CNBX Pharmaceuticals Inc. Files 8-K for Material Agreement

TL;DR

CNBX Pharma signed a big deal, filing an 8-K. Details to follow.

AI Summary

CNBX Pharmaceuticals Inc. entered into a Material Definitive Agreement on January 24, 2025. The filing also includes financial statements and exhibits related to this agreement. The company was formerly known as Cannabics Pharmaceuticals Inc., American Mining Corp, and Thrust Energy Corp.

Why It Matters

This 8-K filing indicates a significant new development for CNBX Pharmaceuticals Inc., potentially impacting its business operations and future financial performance.

Risk Assessment

Risk Level: medium — Material Definitive Agreements can introduce significant new risks or opportunities, requiring further analysis to determine the precise impact.

Key Players & Entities

• CNBX Pharmaceuticals Inc. (company) — Registrant
• January 24, 2025 (date) — Date of earliest event reported
• Cannabics Pharmaceuticals Inc. (company) — Former company name
• American Mining Corp (company) — Former company name
• Thrust Energy Corp. (company) — Former company name

FAQ

Key Financial Figures

• $55,000 — ssory Note which tenders the Company of $55,000 immediately and up to $850,000 over the
• $850,000 — ompany of $55,000 immediately and up to $850,000 over the term of the Note subject to ce

Filing Documents

• cnbx_8k.htm (8-K) — 26KB
• cnbx_ex1001.htm (EX-10.1) — 81KB
• 0001683168-25-000583.txt ( ) — 295KB
• cnbx-20250124.xsd (EX-101.SCH) — 3KB
• cnbx-20250124_lab.xml (EX-101.LAB) — 33KB
• cnbx-20250124_pre.xml (EX-101.PRE) — 22KB
• cnbx_8k_htm.xml (XML) — 3KB

01

Item 1.01. Entry into a Material Definitive Agreement. On January 24 th , 2025, the Company and an institutional investor executed a 9 month Convertible Promissory Note which tenders the Company of $55,000 immediately and up to $850,000 over the term of the Note subject to certain conditions. Per the terms of the Agreement, there is a 9% OID, and carries interest at 10% per annum. The Company has an open right of redemption at 125% of face value. The Investor has agreed that neither it nor any of its affiliates shall engage in any short-selling or hedging of our Common Stock during any time during the term of the Agreements. Pursuant to the Agreements, the Company is required to register all shares which the investor may acquire. The foregoing is a summary description of certain terms of the Agreements. For a full description of all terms, please refer to the copy of the Agreements which are filed herewith as Exhibits 10.1 et seq. to this Current Report on Form 8-K and incorporated herein by reference. All interested parties are encouraged to read the entire text of the listed Agreements.

Financial Statements and Exhibits

Financial Statements and Exhibits. 10.1 Convertible Promissory Note 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2 SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CNBX PHARMACEUTICALS INC. Date: January 29, 2025 By: /s/ Eyal Barad Eyal Barad Director, CEO 3

View Full Filing

View this 8-K filing on SEC EDGAR